Mammoth Biosciences
Xin Miao is a seasoned professional with extensive experience in assay development and product development within the biotechnology sector. Currently serving as Senior Director of Assay Development at Mammoth Biosciences since October 2018, Xin previously held the position of Director of Assay Development at GRAIL, Inc. from June 2017 to April 2018, and Associate Director of Product Development at Cirina from August 2016 to May 2017. Prior roles include Senior Manager of R&D at Ion Torrent Systems and Sr. Staff Scientist at Affymetrix, as well as a Scientist position at Parallele Bioscience. Xin Miao earned a PhD in Molecular Biology from The University of British Columbia and a BSc in Biology-Chemistry from the University of New Brunswick.
This person is not in any teams
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.